Law360, New York (December 21, 2011, 8:37 PM ET) -- An Illinois federal judge on Tuesday denied an attempt by Novartis Pharmaceuticals Corp. and others to dismiss a suit they brought against Akorn Inc. over a patent for cystic fibrosis medication, finding that Akorn should still get a chance to have the patent declared invalid.
Despite a new agreement from plaintiffs Novartis, Seattle Children's Hospital, and Novartis Vaccines and Diagnostics Inc. not to sue Akron for infringement of the patent-in-suit, U.S. District Judge Robert M. Dow Jr., ruled that Akorn can move forward with an attempt...
Novartis, Others Can't Stop Generic Tobramycin Suit
To view the full article, take a free trial now.
